14 July 2014 - PHARMAC is pleased to announce the decision to award the tender to Norgine for Sole Subsidised Supply Status and Hospital Supply Status for rifaximin (Xifaxan) that was included in the 2013/2014 Invitation to Tender, dated 07 November 2013.  In summary, the effect of the decision is that:

• Rifaximin will be funded for the treatment of hepatic encephalopathy from 1 August 2014 (see also the 30 June 2014 tender notification; and
• Rifaximin funding will be subject to Special Authority criteria in the community and restrictions in DHB hospitals

A proposal to list rifaximin with Special Authority criteria was subject of a consultation letter dated 14 January 2013, which can be found on PHARMAC’s website.

For more details, go to: http://www.pharmac.health.nz/news/notification-2014-07-14-rifaximin/